Janux Therapeutics, Inc. (JANX)

Market Cap	2.57B
Revenue (ttm)	13.05M
Net Income (ttm)	-60.54M
Shares Out	52.48M
EPS (ttm)	-1.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	378,461
Open	48.34
Previous Close	49.01
Day's Range	47.61 - 49.33
52-Week Range	7.79 - 65.60
Beta	3.52
Analysts	Strong Buy
Price Target	65.10 (+32.97%)
Earnings Date	Nov 6, 2024

About JANX

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company’s clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 11, 2021
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: JANX
• Website: https://www.januxrx.com

Financial Performance

In 2023, Janux Therapeutics's revenue was $8.08 million, a decrease of -6.14% compared to the previous year's $8.61 million. Losses were -$58.29 million, -7.56% less than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for JANX stock is "Strong Buy." The 12-month stock price forecast is $65.1, which is an increase of 32.97% from the latest price.

Price Target

$65.1

(32.97% upside)

Analyst Consensus: Strong Buy